## NH-bis(PEG4-C2-NH-Boc)

| 2182601-75-  | -6   |   |
|--|--|---|
| C <sub>30</sub> H <sub>61</sub> N <sub>3</sub> O <sub>12</sub> |  |   |
| 655.82   |  |   |
| PROTAC Lin   | kers   |   |
| PROTAC   |  |   |
| Pure form  | -20°C  | 3 years   |
|  | 4°C  | 2 years   |
| n solvent  | -80°C  | 6 months  |
|  | -20°C  | 1 month   |
|  | 182601-75<br><sup>2</sup> <sub>30</sub> H <sub>61</sub> N <sub>3</sub> O <sub>12</sub><br>55.82<br>PROTAC Lin<br>PROTAC<br>Pure form | 182601-75-6<br>5 <sub>30</sub> H <sub>61</sub> N <sub>3</sub> O <sub>12</sub><br>55.82<br>PROTAC Linkers<br>PROTAC<br>Pure form -20°C<br>4°C<br>180°C |

| BIOLOGICAL ACTIVITY       |  |  |  |
|---------------------------|--|--|--|
| BIOLOGICIAL ACTIVITY      |  |  |  |
| Description               | NH-bis(PEG4-C2-NH-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> .  |  |  |
| IC <sub>50</sub> & Target | PEGs   |  |  |
| In Vitro                  | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |  |  |

## REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr. Suite O. Menmouth Junction NL 08952, USA

Product Data Sheet

## RedChemExpress ®